Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says

Executive Summary

Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said

You may also be interested in...



Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche

Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained

Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche

Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained

Genentech Avastin Early Sales Data Suggest Broad Use In Colorectal Cancer

Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS043795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel